Hikma Pharmaceuticals Plc Hikma announces sale of Ben Venue manufacturing (8852G)
November 25 2015 - 3:45AM
UK Regulatory
TIDMHIK
RNS Number : 8852G
Hikma Pharmaceuticals Plc
25 November 2015
Hikma announces sale of Ben Venue manufacturing facilities to
Xellia Pharmaceuticals
London, 25 November 2015 - Hikma Pharmaceuticals PLC ("Hikma")
(LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY), (rated Ba1 Moody's /
BB+ S&P, both stable), the fast growing multinational
pharmaceutical group, today announces it has agreed the sale of
manufacturing facilities previously owned by Ben Venue
Laboratories, Inc ("Ben Venue") based in Bedford, Ohio, to Xellia
Pharmaceuticals ("Xellia").
In 2014, Hikma acquired the Ben Venue assets from Boehringer
Ingelheim, following its agreement to purchase the assets of
Bedford Laboratories. Under the terms of the agreement announced
today, Xellia has acquired substantial parts of the Ben Venue site,
including four sterile injectable manufacturing plants. These
plants are not currently operational. Hikma will retain the Quality
and Development Centre ("QDC"), an independent building with
research and development laboratories, which has been integral to
the tech transfer of the Bedford products to Hikma's own
manufacturing facilities. Since Hikma acquired the Ben Venue site
in September 2014, it has transferred a large number of modern,
high quality machines, including lyophlisers and filling lines, to
its manufacturing facilities in Portugal, Germany and the US.
Said Darwazah, Chairman and Chief Executive Officer of Hikma
commented: "We are very pleased to see that Xellia plans to restart
commercial operations at the Ben Venue site, which will create jobs
and further support the Bedford community. We have successfully
transferred equipment from Ben Venue to our different manufacturing
sites, and will continue to benefit from the exceptional
capabilities and skills of the Quality and Development Centre and
the Bedford R&D teams on-site."
-- ENDS --
Enquiries
Hikma Pharmaceuticals PLC
Susan Ringdal, VP Corporate Strategy and Investor Relations +44
(0)20 7399 2760/ +44 7776 477050
Zeena Murad, Investor Relations Manager +44 (0)20 7399 2768/ +44
7771 665277
FTI Consulting
Ben Atwell/ Matthew Cole +44 (0)20 3727 1000
About Hikma
Hikma Pharmaceuticals PLC is a fast growing multinational group
focused on developing, manufacturing and marketing a broad range of
both branded and non-branded generic and in-licensed products.
Hikma operates through three businesses: "Injectables", "Branded"
and "Generics", based principally in the United States, the Middle
East and North Africa ("MENA") and Europe. In 2014, Hikma achieved
revenues of $1,489 million and profit attributable to shareholders
of $299 million.
About Xellia
Xellia Pharmaceuticals is a specialty pharmaceutical company
focused on providing important anti-infective treatments against
serious and often life-threatening infections. With over 100 years
of experience Xellia is a leading developer, manufacturer and
trusted supplier of fermented and semi-synthetic Active
Pharmaceutical Ingredients (APIs) and Injectable Finished Dosage
Forms (FDFs) to the pharmaceutical industry. The Company has
growing sales in more than 70 countries to over 500 customers
across the healthcare industry. Headquartered in Copenhagen,
Denmark, Xellia has global facilities including operational and
manufacturing capabilities in Denmark, USA, Hungary and China, and
currently employs over 1,000 people.
Xellia is a leading supplier of vancomycin and colistimethate
sodium (CMS) which together combat life-threatening, multi-drug
resistant bacterial infections across Gram-positive and
Gram-negative species. Xellia is also developing novel antibiotics
effective against MDR Gram-negative bacteria in a development
project with SINTEF Materials and Chemistry (Trondheim) and the
Statens Serum Institut (Copenhagen), supported by a grant from the
Research Council of Norway. Since July 2013, Xellia has been wholly
owned by Novo A/S, the holding Company of the Novo Group. Further
information about Xellia can be found at: www.xellia.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
STRGMMZMRKGGKZG
(END) Dow Jones Newswires
November 25, 2015 03:45 ET (08:45 GMT)
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jun 2024 to Jul 2024
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jul 2023 to Jul 2024